Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
ZB

NASDAQ · ZBIO

Zenas BioPharma, Inc.

Healthcare · Biotechnology

$27.62

Down-$0.77 (-2.71%)

Updated Nov 3, 2026, 8:44 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.69B
P/E ratio
-9.52
Dividend yield
0.00%
52-week range
$16.41 – $34.05
Volume
408.89K
Avg. volume
419.1K

Price performance · ZBIO

ZBIO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ZBIO closed at $27.62 after 21 trading sessions, down 0.75% for the selected period.

Last close
$27.62
Period change
-0.75%
Period low
$24.84
Period high
$28.77
Daily close
View OHLC price history
ZBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$28.47$29.09$27.145$27.62408.89K
Oct 30, 2026$28.35$29.11$27.91$28.39358.07K
Oct 29, 2026$29.08$29.61$28.3739$28.76373.03K
Oct 28, 2026$27.10$29.07$27.03$28.77394.28K
Oct 27, 2026$27.09$28.23$26.72$27.30581.01K
Oct 26, 2026$27.18$28.18$26.68$27.24371.65K
Oct 23, 2026$28.00$28.33$26.73$26.87377.55K
Oct 22, 2026$27.95$28.83$27.51$28.23406.02K
Oct 21, 2026$28.47$29.44$27.895$28.08483.99K
Oct 20, 2026$26.38$29.705$26.38$28.18549.02K
Oct 19, 2026$25.08$27.55$25.08$26.71696.54K
Oct 16, 2026$25.36$25.96$24.51$24.84661.8K
Oct 15, 2026$24.96$25.94$24.25$25.40471.94K
Oct 14, 2026$24.82$26.49$24.39$24.86425.05K
Oct 13, 2026$26.11$27.00$25.035$25.16519.66K
Oct 12, 2026$26.93$27.49$26.295$26.40602.49K
Oct 9, 2026$26.18$27.64$26.18$27.26429.82K
Oct 8, 2026$27.98$27.98$25.51$26.24557.49K
Oct 7, 2026$26.89$28.86$26.775$28.18509.23K
Oct 6, 2026$27.87$28.14$26.28$26.94357.6K
Oct 5, 2026$28.47$29.06$27.77$27.831.13M

Latest ZBIO news

The latest Smart Investors Daily articles mentioning ZBIO.

Stock researchCompany · Overview

ZBIO research

Overview

Company profile and research snapshot.

Company profile

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.33
Implied upside
—
Analysts
—
ZBIO recent ratings
DateFirmRatingTarget
Oct 13, 2026HC Wainwright & Co.Buy—
Sep 30, 2026HC Wainwright & Co.Buy—
Sep 30, 2026WedbushOutperform—
Sep 30, 2026CitigroupBuy—
Aug 14, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release

Zenas BioPharma recently presented new Phase 3 INDIGO data for obexelimab in immunoglobulin G4-related disease at the 6th International Symposium on IgG4-Related Disease, highlighting longer-term flare protection, reduced glucocorticoid use, and a favorable safety profile in an open-label extension. The company also reported that patients largely preserved vaccine responses and pre-existing immunity during a planned treatment-free window, underscoring obexelimab’s potential to control...

Yahoo · Oct 12, 2026

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52 – – Initial open-label extension sub-study findings demonstrated vaccine responses following a treatment-free window – – These new findings add to the clinical evidence supporting obexelimab’s investigational role as a reversible,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By